SEI Investments’s Teva Pharmaceuticals TEVA Stock Holding History

SEI Investments’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4M	Sell	1,105,005 -77,746	-7%	-$2.59M	0.03%	535
2026 Q1	$35.6M	Buy	1,182,751 +217,487	+23%	+$7M	0.03%	543
2025 Q4	$30.1M	Buy	965,264 +61,395	+7%	+$1.51M	0.03%	571
2025 Q3	$18.3M	Sell	903,869 -59,958	-6%	-$1.05M	0.02%	764
2025 Q2	$16.2M	Buy	963,827 +13,061	+1%	+$211K	0.02%	785
2025 Q1	$14.6M	Buy	950,766 +457,730	+93%	+$8.18M	0.02%	818
2024 Q4	$10.9M	Buy	493,036 +25,089	+5%	+$456K	0.01%	950
2024 Q3	$8.43M	Buy	467,947 +23,566	+5%	+$412K	0.01%	1051
2024 Q2	$7.22M	Sell	444,381 -12,941	-3%	-$199K	0.01%	1060
2024 Q1	$6.45M	Buy	457,322 +4,000	+0.9%	+$50.4K	0.01%	1089
2023 Q4	$4.73M	Buy	453,322 +95,489	+27%	+$892K	0.01%	1211
2023 Q3	$3.65M	Buy	+357,833	New	+$3.33M	0.01%	1314
2022 Q3	–	Sell	-134,601	Closed	-$1.01M	–	2731
2022 Q2	$1.01M	Sell	134,601 -131,339	-49%	-$1.14M	﹤0.01%	1829
2022 Q1	$2.5M	Sell	265,940 -243	-0.1%	-$2.03K	0.01%	1458
2021 Q4	$2.13M	Buy	266,183 +92	+0%	+$830	﹤0.01%	1559
2021 Q3	$2.59M	Hold	266,091	–	–	0.01%	1402
2021 Q2	$2.63M	Buy	+266,091	New	+$2.82M	0.01%	1382
2019 Q2	–	Sell	-20,774	Closed	-$326K	–	2752
2019 Q1	$326K	Sell	20,774 -157,669	-88%	-$2.78M	﹤0.01%	2092
2018 Q4	$3.84M	Buy	178,443 +49	+0%	+$1K	0.01%	1024
2018 Q3	$3.84M	Buy	178,394 +16,153	+10%	+$375K	0.01%	997
2018 Q2	$3.95M	Buy	162,241 +34,305	+27%	+$700K	0.01%	1044
2018 Q1	$2.19M	Sell	127,936 -546,069	-81%	-$10.7M	0.01%	1177
2017 Q4	$12.8M	Buy	674,005 +140,493	+26%	+$2.11M	0.04%	507
2017 Q3	$9.39M	Sell	533,512 -1,187,954	-69%	-$26.7M	0.03%	620
2017 Q2	$57.2M	Buy	1,721,466 +875,789	+104%	+$27.1M	0.23%	84
2017 Q1	$27.1M	Buy	845,677 +77,015	+10%	+$2.63M	0.12%	189
2016 Q4	$27.9M	Sell	768,662 -63,798	-8%	-$2.55M	0.13%	161
2016 Q3	$38.3M	Sell	832,460 -59,214	-7%	-$3.09M	0.19%	115
2016 Q2	$44.8M	Buy	891,674 +132,153	+17%	+$7.04M	0.27%	77
2016 Q1	$40.6M	Buy	759,521 +32,185	+4%	+$1.89M	0.25%	96
2015 Q4	$47.7M	Buy	727,336 +50,082	+7%	+$3.09M	0.29%	69
2015 Q3	$38.2M	Buy	677,254 +211,968	+46%	+$13.7M	0.35%	58
2015 Q2	$27.5M	Sell	465,286 -136,764	-23%	-$8.44M	0.25%	104
2015 Q1	$37.5M	Sell	602,050 -1,465	-0.2%	-$85.2K	0.33%	71
2014 Q4	$34.7M	Buy	+603,515	New	+$33.6M	0.31%	79

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

SEI Investments's TEVA Position: Q2 2026 in Review

SEI Investments reduced its Teva Pharmaceuticals (TEVA) stake by 6.6% in Q2 2026, selling an estimated $2.59M and leaving 1,105,005 shares worth $37.4M. The position accounts for 0.03% of the portfolio, ranked #535.

SEI Investments first reported a position in TEVA in Q4 2014 and has held it in 35 quarters since. The position peaked at $57.2M in Q2 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

SEI Investments held 1,105,005 shares of Teva Pharmaceuticals worth $37.4M as of Q2 2026.
SEI Investments sold 77,746 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
Teva Pharmaceuticals made up 0.03% of SEI Investments's portfolio in Q2 2026, its #535 holding.
SEI Investments first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 35 quarters since.
SEI Investments's Teva Pharmaceuticals position peaked at $57.2M in Q2 2017.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.